Our study also identifies DAPK1 as a putative therapeutic target for septic AKI and demonstrates that pharmacological deactivation or genetic ablation of DAPK1 in combination with MyD88 inhibitor provides better efficacy against septic AKI. This evidence concerns the gene DAPK1 and acute kidney injury.